RECOGNIFY LIFE SCIENCES
Recognify Life Sciences is an entity developing a treatment for Cognitive Impairment associated with Schizophrenia ("CIAS").
More informations about "Recognify Life Sciences"
Recognify Life Sciences
By combining scientific innovation with deep domain expertise, we are determined to deliver ground-breaking treatment for those suffering with a debilitating disorder effecting millions …See details»
Team - Recognify Life Sciences
Florian Brand, Co-CEO, atai Life Sciences, Board Member. Florian is the co-founder and Chief Executive Officer of ATAI Life Sciences, a global biotech company builder with the vision of …See details»
Recognify Life Sciences - Crunchbase Company Profile & Funding
Recognify Life Sciences is an entity developing a treatment for Cognitive Impairment associated with Schizophrenia ("CIAS"). Recognify Life Sciences was acquired by ATAI Life Sciences on …See details»
Recognify Life Sciences to Commence Phase 2a Study in Cognitive ...
Apr 6, 2021 · Recognify Life Sciences, an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive …See details»
Recognify Life Sciences to Commence Phase 2a Study in Cognitive ...
Recognify Life Sciences is a biotech company leveraging a Phase 2 ready asset to treat Cognitive Impairment Associated with Schizophrenia (CIAS). Recognify's mission is to provide pro …See details»
Recognify Life Sciences acquired by ATAI Life Sciences - Crunchbase
Jan 12, 2021 · Recognify Life Sciences Recognify Life Sciences is an entity developing a treatment for Cognitive Impairment associated with Schizophrenia ("CIAS"). Acquiring …See details»
Recognify Life Sciences - PitchBook
Nov 6, 2020 · Information on acquisition, funding, cap tables, investors, and executives for Recognify Life Sciences. Use the PitchBook Platform to explore the full profile.See details»
atai Life Sciences Acquires Majority Stake in Recognify Life …
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health …See details»
Recognify Life Sciences to Commence Phase 2a Study in Cognitive ...
Apr 6, 2021 · Recognify's mission is to provide pro-cognitive treatments solutions to mental health disorders, with a primary focus on schizophrenia. The company operates as part of the atai …See details»
atai Life Sciences Announces Supportive Interim Data …
Nov 1, 2021 · The atai RL-007 trials are being conducted by Recognify Life Sciences, an atai Life Sciences platform company. “With these data, from the interim analysis of the ongoing Phase 2a trial, we are encouraged to …See details»
Recognify Life Sciences to Commence Phase 2a Study in Cognitive ...
Apr 6, 2021 · Recognify Life Sciences, Inc., an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive …See details»
Blog 3 — Recognify Life Sciences
Recognify Life Sciences, an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment …See details»
Gary Walker, PhD - Recognify Life Sciences | LinkedIn
May 9, 2016 · I love science and bringing new products to the market to advance patient care. I… · Experience: Recognify Life Sciences · Education: University of California, Berkeley · Location: San ...See details»
Recognify Life Sciences to Commence Phase 2a Study in Cognitive ...
Apr 6, 2021 · Recognify's mission is to provide pro-cognitive treatments solutions to mental health disorders, with a primary focus on schizophrenia. The company operates as part of the atai …See details»
atai Life Sciences Acquires Majority Stake in Recognify Life …
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health …See details»
atai Life Sciences Announces Successful Outcome of Phase 2a …
Dec 14, 2021 · Recognify Life Sciences, an atai Life Sciences platform company, is conducting the current and upcoming RL-007 trials in CIAS. “The impact of cognitive impairment in …See details»
atai Life Sciences Acquires Majority Stake in Recognify Life …
Jan 12, 2021 · atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has acquired a majority …See details»
About 1 - Recognify Life Sciences
Preclinical evidence: RL-007 demonstrated pro-cognitive effects in healthy young animals, age-associated memory loss, and models of cholinergic-deficits. RL-007 also showed anxiolytic …See details»
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL …
Dec 19, 2022 · atai Life Sciences’ subsidiary, Recognify Life Sciences, is conducting this study. By pooling resources and best practices, atai aims to responsibly accelerate the development …See details»
atai Life Sciences Announces Successful Outcome of Phase 2a
Dec 14, 2021 · Recognify Life Sciences, an atai Life Sciences platform company, is conducting the current and upcoming RL-007 trials in CIAS. “The impact of cognitive impairment in …See details»